Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Discovery of Novel Plant-Derived Compounds with Antibacterial Activities
share announcement

Discovery of Novel Plant-Derived Compounds with Antibacterial Activities

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 4570

Special Issue Editor

Prof. Dr. Ying Li

E-Mail Website
Guest Editor
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Interests: antibacterial infections; plant-derived compounds; natural biomedical polymers; drug delivery nanomedicine

Special Issue Information

Dear Colleagues,

At present, infectious diseases caused by bacterial infections are a serious threat to human public health and safety. In the treatment of bacterial infectious diseases, since the discovery of penicillin as a drug whose properties could kill staphylococci in 1929 by Alexander Fleming, the field gradually entered the era of control and treatment of bacterial infectious diseases. However, the increasing unnecessary use of antibiotics accelerates the evolution of pathogenic bacteria. As a consequence, a large number of drug-resistant bacteria and multidrug-resistant bacteria have continued to appear in recent years. Today, there is a trend towards utilizing plant-derived compounds, applied in various antibacterial infections field, including pharmaceutical drug delivery, clinical therapies, surgeries, cosmetics, medical devices, marketed products, and much more. This Special Issue seeks to capitalize on this trend to highlight a myriad of novel plant-derived antibacterial compounds, specifically designed for antibacterial applications. We invite both reviews and original articles that shed light on past challenges via the use of natural plant-derived compounds to combat bacterial infections. Potential topics include but are not limited to: plant-derived small molecules and their nanoparticles; biocompatible and biodegradable plant-derived polymers; natural hydrogels, which act as multifunctional biomaterials; drug delivery carriers or regulatory platforms, with applications that range curing bacterial infections to enhancing therapies, as well as tissue engineering and regenerative medicine.

Prof. Dr. Ying Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibacterial infections
  • plant-derived compounds
  • natural biomedical polymers
  • drug delivery
  • nanomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

32 pages, 13639 KiB  
Article
Covalent Conjugates of Allylbenzenes and Terpenoids as Antibiotics Enhancers with the Function of Prolonged Action
by Igor D. Zlotnikov, Maria P. Davydova, Milan R. Danilov, Sergey S. Krylov, Natalya G. Belogurova and Elena V. Kudryashova
Pharmaceuticals 2023, 16(8), 1102; https://doi.org/10.3390/ph16081102 - 4 Aug 2023
Cited by 4 | Viewed by 1345
Abstract
The drug resistance of pathogenic bacteria is often due efflux pumps—specific proteins that remove foreign compounds from bacterial cells. To overcome drug resistance, adjuvants are often used that can inhibit efflux pumps or other systems that ensure the resistance of bacteria to the [...] Read more.
The drug resistance of pathogenic bacteria is often due efflux pumps—specific proteins that remove foreign compounds from bacterial cells. To overcome drug resistance, adjuvants are often used that can inhibit efflux pumps or other systems that ensure the resistance of bacteria to the action of antibiotics. We assumed that a new level of effectiveness with the use of an antibiotic + an adjuvant pair could be achieved by their joint delivery into the pathogen. To test this hypothesis, we constructed a series of molecular carriers based on poly-(olygo-, dendry)mers based on cyclodextrin-grafted PEI or mannan, as well as glycol chitosan, covalently bound to antibiotic, adjuvant, and the oligosaccharide ligand to the macrophage mannose receptor (CD206), which we studied earlier and showed high efficiency and selectivity of delivery of a therapeutic “cargo” to macrophages. Moxifloxacin was used as an antibiotic, and terpenoid and allylbenzene compounds were used as adjuvants, for which we previously discovered the ability to inhibit bacterial efflux pumps. We show that: (a) the resulting structures were stable in vitro for a long time (up to 10 days); (b) they were adsorbed on bacterial cells, providing a local increase in the concentration of the antibiotic and adjuvant in pathogen cells; (c) they were internalized by bacterial cells, ensuring the accumulation of both antibiotic and adjuvant inside bacterial cells; (d) the adjuvant, after entering the bacterial cell, provided inhibition of the efflux pumps; (e) due to this action of the adjuvant, combined with the targeted delivery by the carrier, the antibiotic’s half-life in rats increased by more than 2 times, the effective concentration of the drug in the blood plasma (AUC) increased up to 8–10 times; (f) a significant increase in the effectiveness of the antibacterial action against Gram+ and Gram- cells was achieved (up to 3 times). Potentially, such an approach would significantly increase the effectiveness of therapies for a number of infectious and other diseases, reduce the dosage of antibiotics, shorten the duration of treatment, and reduce the risk of developing bacterial resistance. Moreover, the use of a polymer carrier with covalently bound organic molecules of different structures will avoid problems linked to different (suboptimal) solubility and bio-distribution of the administered molecules, which would be almost inevitable when using the same compounds separately. It would be very difficult to find antibiotic/adjuvant pairs that simultaneously achieve optimal concentrations in the same target cells. In our case, terpenoids and alkylbenzenes used as adjuvants are practically insoluble as individual compounds, and their unacceptable pharmacological properties would not allow them to be used as efflux pump inhibitors. Full article
(This article belongs to the Special Issue Discovery of Novel Plant-Derived Compounds with Antibacterial Activities)
►▼ Show Figures

Figure 1

17 pages, 2885 KiB  
Article
Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections
by Mariana Romo-Castillo, Victor Andrés Flores-Bautista, Silvia Laura Guzmán-Gutiérrez, Ricardo Reyes-Chilpa, Mayra León-Santiago and Victor Manuel Luna-Pineda
Pharmaceuticals 2023, 16(6), 839; https://doi.org/10.3390/ph16060839 - 5 Jun 2023
Cited by 2 | Viewed by 2683
Abstract
Increased antibiotic resistance presents a health problem worldwide. The World Health Organization published a list of pathogens considered a priority for designing new treatments. Klebsiella pneumoniae (Kp) is a top-priority microorganism, highlighting the strains that produce carbapenemases. Developing new efficient therapies or complementing [...] Read more.
Increased antibiotic resistance presents a health problem worldwide. The World Health Organization published a list of pathogens considered a priority for designing new treatments. Klebsiella pneumoniae (Kp) is a top-priority microorganism, highlighting the strains that produce carbapenemases. Developing new efficient therapies or complementing existing treatments is a priority, and essential oils (EOs) provide an alternative. EOs could act as antibiotic adjuvants and enhance antibiotic activity. Employing standard methodologies, the antibacterial activity of the EOs and their synergic effect with antibiotics were detected. A string test was used to identify the impact of the EOs over the hypermucoviscosity phenotype presented by Kp strains, and Gas Chromatography–Mass Spectrometry analysis identified EOs and the composition of EOs. The potential of EOs for designing synergistic therapies with antibiotics to combat the infection of KPC diseases was demonstrated. In addition, the alteration of the hypermucoviscosity phenotype was shown as the principal mechanism of a synergic action between EOs and antibiotics. The differential composition of the EOs lets us identify some molecules that will be analyzed. Synergic activity of EOs and antibiotics can provide a solid platform for combating multiresistant pathogens that represent a severe health sector problem, such as Kp infections. Full article
(This article belongs to the Special Issue Discovery of Novel Plant-Derived Compounds with Antibacterial Activities)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop